Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | PRKCB | P05771 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | PRKCH | P24723 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL9053410 | 0.94 | LPAR5 (0.61) | LPAR5USP2HTTLPAR1LPAR3 | |
| SCHEMBL2454903 | 0.91 | LPAR5 (0.52) | LPAR5USP2HTTLPAR1LPAR3 | |
| SCHEMBL1445519 | 0.89 | USP2 (0.62) | LPAR5USP2HTTLPAR1LPAR3 | |
| SCHEMBL80315 | 0.88 | LPAR5 (0.55) | LPAR5USP2HTTLPAR1LPAR3 | |
| SCHEMBL409138 | 0.87 | LPAR5 (0.64) | LPAR5USP2HTTLPAR1LPAR3 | |
| SCHEMBL7199096 | 0.82 | USP2 (0.48) | LPAR5USP2HTTLPAR1LPAR3 | |
| SCHEMBL9608647 | 0.80 | USP2 (0.64) | LPAR5USP2HTTLPAR1LPAR3 | |
| Hydrochloric Acid SCHEMBL9706832 | 0.80 | USP2 (0.51) | LPAR5USP2HTTLPAR1LPAR3 | |
| Hydrochloric Acid SCHEMBL9706844 | 0.80 | USP2 (0.51) | LPAR5USP2HTTLPAR1LPAR3 | |
| SCHEMBL9837924 | 0.79 | LPAR5 (0.57) | LPAR5USP2HTTLPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11110175-B2 | Compositions with permeation enhancers for drug delivery | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200138710-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3512501-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | Children's Medical Center Corporation (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3331547-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | Children's Medical Center Corporation (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2018053140-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2017024282-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20150104645-A1 | MAGNETIC NANOFLAKES | GABAY ALEXANDR (US) | 2015-04-16 | — | — | US | disclosed |
| US-8822410-B2 | Tympanic membrane permeating ear drops and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120021219-A1 | MAGNETIC NANOFLAKES | ELECTRON ENERGY CORPORATION | 2012-01-26 | — | — | US | disclosed |
| US-20120019342-A1 | Magnets made from nanoflake precursors | ELECTRON ENERGY CORPORATION | 2012-01-26 | — | — | US | disclosed |
| EP-0831762-A4 | ORAL CARE ULTRAMULSION BASED PRODUCTS | WHITEHILL ORAL TECH INC (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0831762-A1 | ORAL CARE ULTRAMULSION BASED PRODUCTS | WHITEHILL ORAL TECHNOLOGIES INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0600032-B1 | HAIR SPRAY COMPOSITIONS | PROCTER & GAMBLE (US) | 1997-11-26 | — | — | EP | disclosed |
| US-5665374-A | Ultramulsion containing interdental delivery devices | WHITEHILL ORAL TECHNOLOGIES, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5651959-A | SILICONE DISPERSION IN SURFACTANTS | WHITEHILL ORAL TECHNOLOGIES, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0525078-B1 | ANTI-LICE TREATMENT COMPOSITIONS | PROCTER & GAMBLE (US) | 1997-07-23 | — | — | EP | disclosed |
| US-5645841-A | Ultramulsion based oral care rinse compositions | WHITEHILL ORAL TECHNOLOGIES, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996039249-A1 | ULTRAMULSION BASED PAINT AND COATING PRODUCTS | WHITEHILL ORAL TECHNOLOGIES, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996039116-A1 | ORAL CARE ULTRAMULSION BASED PRODUCTS | WHITEHILL ORAL TECHNOLOGIES, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5292504-A | Pyrethrins | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11110175-B2 | Compositions with permeation enhancers for drug delivery | ABCB11, MMP1, SLC47A1 | ADRA1D 2401/4885ADRA1B 1460/4885LPAR5 1588/4885 |
| US-20200138710-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | ABCB11, CFTR, MMP1 | ADRA1D 2403/4885ADRA1B 1603/4885LPAR5 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.